Marnix L. Bosch

Dr. Bosch joined the company in 2000 and has been serving as the Chief Technical Officer for a number of years. In this capacity, he plays a key role in the preparation and submission of the regulatory applications, as well as the ongoing development of the product lines, and ongoing development and/or acquisition of new technologies. Dr. Bosch led the process of designing the protocols and managed the successful preparation and submission of the Investigational New Drug (IND) applications for FDA approval to conduct clinical trials for prostate cancer, brain cancer, ovarian cancer, and multiple other cancers. He also led the processes for other regulatory submissions in both the U.S. and abroad (including the successful applications for orphan drug status in both the U.S. and Europe for DCVax-L for brain cancer). He spearheaded the development of the manufacturing and quality control processes and is working with Cognate BioServices, Inc. on the next-generation further development of these processes. Prior to joining Northwest Biotherapeutics in 2000, Dr. Bosch worked at the Dutch National Institutes of Health (RIVM) as head of the Department of Molecular Biology, as well as in academia as a professor of Pathobiology. He has authored more than 40 peer-reviewed research publications in immunology and virology and is an inventor of several patent applications on dendritic cell product manufacturing.